Nadroparin calcium

Nadroparin calcium

Clinical data
Trade names	Fraxiparine, Fraxodi
AHFS/Drugs.com	International Drug Names
Routes of administration	SC (except for haemodialysis)
ATC code	B01AB06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only
Pharmacokinetic data
Bioavailability	89% (SC dose)
Elimination half-life	3.7 hours (SC dose)
Excretion	clearance 21.4mL/min (+/- 7)
Identifiers
IUPAC name (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
CAS Number	9005-49-6 N
DrugBank	DB08813 N
ChemSpider	none
UNII	1K5KDI46KZ
KEGG	D07510 N
Chemical and physical data
Molar mass	4300 g/mol
NY (what is this?)  (verify)

Nadroparin (trade name, Fraxiparine or Fraxodi) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.^[1]

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.^[1]

References

External links

• http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
• http://www.mayoclinic.com/health/drug-information/DR600971
• Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417.